Skip to content

Study · Systematic review · 2021

6 results

Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.

Avgerinos I, Manolopoulos A, Michailidis T, Kitsios K, Liakos A, Karagiannis T, Dimitrakopoulos K, Matthews DR, Tsapas A, Bekiari E

Diabetes, obesity & metabolism6 Jan 2021Cited by 31 (Europe PMC)

PMID33300282 (opens in a new tab)DOI10.1111/dom.14291 (opens in a new tab)PepBankPUB-33300282
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 1 diabetes on insulin, a network meta-analysis found that liraglutide reduced body weight.

    In plain wordsIn adults with type 1 diabetes, liraglutide reduced body weight in pooled trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SGLT inhibitors, exenatide daily, liraglutide and metformin reduced body weight and total daily insulin dose, while liraglutide and SGLT inhibitors reduced blood pressure.
    2 context sentences
    Summary · context
    To assess the efficacy and safety of glucose-lowering drugs used as an adjunct to insulin therapy in adults with type 1 diabetes.
    Summary · context
    We included 58 trials comprising 13 216 participants.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 1 diabetes on insulin, a network meta-analysis found that liraglutide reduced total daily insulin dose.

    In plain wordsIn adults with type 1 diabetes, liraglutide lowered the total daily insulin dose in pooled trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal daily insulin dose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SGLT inhibitors, exenatide daily, liraglutide and metformin reduced body weight and total daily insulin dose, while liraglutide and SGLT inhibitors reduced blood pressure.
    2 context sentences
    Summary · context
    To assess the efficacy and safety of glucose-lowering drugs used as an adjunct to insulin therapy in adults with type 1 diabetes.
    Summary · context
    We included 58 trials comprising 13 216 participants.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 1 diabetes on insulin, a network meta-analysis found that liraglutide reduced blood pressure.

    In plain wordsIn adults with type 1 diabetes, liraglutide lowered blood pressure in pooled trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseBlood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SGLT inhibitors, exenatide daily, liraglutide and metformin reduced body weight and total daily insulin dose, while liraglutide and SGLT inhibitors reduced blood pressure.
    2 context sentences
    Summary · context
    To assess the efficacy and safety of glucose-lowering drugs used as an adjunct to insulin therapy in adults with type 1 diabetes.
    Summary · context
    We included 58 trials comprising 13 216 participants.
  4. 04HumanSystematic reviewSafety outcome

    In adults with type 1 diabetes on insulin, a network meta-analysis found that liraglutide increased the incidence of nausea.

    In plain wordsIn adults with type 1 diabetes, liraglutide caused more nausea in pooled trials.

    Peptide
    Liraglutide
    Outcome
    IncreaseNausea incidence
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Diabetic ketoacidosis and genital infections were more frequent with SGLT inhibitors, while exenatide, liraglutide, pramlintide and metformin increased the incidence of nausea.
    2 context sentences
    Summary · context
    To assess the efficacy and safety of glucose-lowering drugs used as an adjunct to insulin therapy in adults with type 1 diabetes.
    Summary · context
    We included 58 trials comprising 13 216 participants.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 1 diabetes on insulin, a network meta-analysis found that SGLT inhibitors, liraglutide, glibenclamide, acarbose and metformin as a group reduced HbA1c compared with placebo, with mean differences ranging from -0.46% to -0.20%.

    In plain wordsIn adults with type 1 diabetes, several diabetes drugs, liraglutide among them, lowered HbA1c more than placebo in pooled trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Overall, sodium-glucose co-transporter (SGLT) inhibitors, liraglutide, glibenclamide, acarbose and metformin reduced HbA1c compared with placebo (MDs ranging from -0.46% [95% CI -0.64% to -0.29%] for empagliflozin to -0.20% [-0.35% to -0.06%] for metformin).
    2 context sentences
    Summary · context
    To assess the efficacy and safety of glucose-lowering drugs used as an adjunct to insulin therapy in adults with type 1 diabetes.
    Summary · context
    We included 58 trials comprising 13 216 participants.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 06HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with type 1 diabetes on insulin, a network meta-analysis found that no drug in the network, liraglutide included, increased the incidence of severe hypoglycaemia.

    In plain wordsIn adults with type 1 diabetes, a pooled analysis found that none of the drugs studied, liraglutide included, increased severe low blood sugar.

    Peptide
    Liraglutide
    Outcome
    No significant changeSevere hypoglycaemia incidence
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    No drug increased the incidence of severe hypoglycaemia.
    2 context sentences
    Summary · context
    To assess the efficacy and safety of glucose-lowering drugs used as an adjunct to insulin therapy in adults with type 1 diabetes.
    Summary · context
    We included 58 trials comprising 13 216 participants.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    12 Oct 2026, 11:11 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.